VIVE News and Press, Viveve Medical Inc. From 01/17/23

Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a...

Topline results of the 12-month primary efficacy endpoint anticipated in January 2023 Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in women ENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medi...

Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trial ENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on wom...

Viveve Medical (NASDAQ: VIVE) , a medical technology company focused on women's health and the treatment of female stress urinary incontinence (“SUI”), has reported its financial results for the third quarter 2022, the period ended Sept. 30, 2022. Highlights of the report incl...

Viveve Medical, Inc. (VIVE) Q3 2022 Results Conference Call November 10, 2022 05:00 PM ET Company Participants Jeannie Swindle - Senior Director, Corporate Communications Scott Durbin - CEO Jim Robbins - SVP, Finance and Administration Presentation ...

Viveve Medical press release ( NASDAQ: VIVE ): Q3 GAAP EPS of -$0.59 beats by $0.07 . Revenue of $17M (+962.5% Y/Y) beats by $15.29M . Gross profit for the third quarter of 2022 was $0.5 million, or 32% of revenue, compared to gross profit of $0.1 million, or...

Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tips PURSUIT clinical trial completion expected by year-end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:...

ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corpor...

Viveve Medical ( NASDAQ: VIVE ) stock rose ~4% on Oct. 4 after the company said that the U.S. Patent and Trademark Office will issue a patent — application no. 16/454,578 — covering Viveve's dual-energy technology to treat female stress urinary ...

Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatmen...